Activity of the antibiotic CP-99,219 (trovafloxacin) in a mixed microflora growth system model of intraabdominal infections in humans

Infectious Diseases in Clinical Practice

Volumn 5, Issue SUPPL. 3, 1996, Pages

  Ross, Robin A ^a,b   Onderdonk, Andrew B ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b CHANNING LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TROVAFLOXACIN;

ABDOMINAL INFECTION; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTEROIDES FRAGILIS; CONTROLLED STUDY; ESCHERICHIA COLI; MODEL; NONHUMAN;

EID: 0029763343     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019048-199606001-00005     Document Type: Article

References (5)

1. Altemeier WA, Culbertson WR, Fullen WD. Intraabdominal abscesses. Adv Surg 1971;5:281-333.
2. Onderdonk AB, Weinstein WM, Sullivan NM, Bartlett JG, Gorbach SL. Experimental intra-abdominal abcesses in rats: quantitative bacteriology of infected animals. Infect Immun 1974;10:1256-9.
3. Weinstein WM, Onderdonk AB, Sullivan NM, Bartlett JG, Gorbach SL. Experimental intra-abdominal abcesses in rats: development of an experimental model. Infect Immun 1974;10:1250-5.
4. Onderdonk AB. Efficacy of trovafloxacin (CP-99,219), a new fluoroquinolone, in an animal model for intraabdominal sepsis. Infect Dis Clin Pract 1996;5 Suppl 3:S117-S119.
5. Girard AE, Girard D, Gootz TD, Faiella JA, Cimochowski CR. In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae and Bacteroides fragilis. Antimicrob Agents Chemother 1995;39:22100-16.